Management of Hyperactivity and Aggression in Autism Spectrum Disorder
Pharmacological Management Framework
- The American Academy of Child and Adolescent Psychiatry recommends pharmacotherapy targeting specific behavioral symptoms for hyperactivity and aggression in individuals with Autism Spectrum Disorder (ASD), with risperidone and aripiprazole being FDA-approved for irritability, and methylphenidate showing moderate efficacy for hyperactivity 1, 2
- Risperidone is FDA-approved for irritability associated with autistic disorder in children and adolescents ages 5-17 years, with demonstrated efficacy for aggression, tantrums, and self-injurious behavior, and a positive response rate of 69% versus 12% on placebo 3
- Aripiprazole is also FDA-approved for the same indication in children ages 6-17 years, with a positive response rate of 56% at 5 mg dose versus 35% on placebo, and significant improvement in irritability, hyperactivity, and stereotypy 3, 4
- Methylphenidate showed a 49% response rate in children with ASD and elevated hyperactivity scores in a large randomized controlled trial, and the DSM-5 now permits concurrent diagnosis of ADHD in individuals with ASD, supporting stimulant use 2, 5, 6, 7
Combined Treatment Approach
- Combining medication with parent training is moderately more efficacious than medication alone for decreasing serious behavioral disturbance and modestly more efficacious for adaptive functioning, according to the American Academy of Child and Adolescent Psychiatry 1, 8, 9
Treatment Algorithm
- The treatment algorithm recommends identifying the primary target symptom, and if aggression/irritability/tantrums predominate, starting with atypical antipsychotic (risperidone or aripiprazole), and if hyperactivity/inattention predominates, considering methylphenidate trial first, with alpha-2 agonist as alternative 1, 3, 5, 8